PCTP contributes to human platelet activation by enhancing dense granule secretion.

Area of Science:

• Biochemistry
• Hematology
• Cell Biology

Background:

• Phosphatidylcholine transfer protein (PCTP) was recently identified to regulate human platelet aggregation.
• The precise role of PCTP in platelet activation, especially following thrombin stimulation and its mechanisms, remained largely unknown.

Purpose of the Study:

• To investigate the role of PCTP in human platelet activation induced by various agonists, including thrombin.
• To elucidate the mechanisms underlying PCTP's contribution to platelet signaling and dense granule secretion.

Main Methods:

• Human platelets were treated with agonists (thrombin, PAR1AP, PAR4AP, convulxin, FcγRIIA) in the presence of a specific PCTP inhibitor (A1).
• Dense and alpha granule secretion, platelet aggregation, cytoplasmic Ca2+ levels, and PKC activity were measured.

Main Results:

• PCTP inhibition significantly reduced dense granule secretion across multiple agonists but only reduced aggregation with low-dose thrombin and PAR4AP.
• PCTP inhibition did not affect alpha granule secretion.
• PCTP inhibition attenuated thrombin-induced increases in cytoplasmic Ca2+ and PKC activity.

Conclusions:

• PCTP plays a significant role in dense granule secretion and early signaling events in human platelets, particularly those mediated by PAR4.
• These findings highlight PCTP as a potential target for modulating platelet function in hemostasis and thrombosis.